KR102061137B1 - 금속효소 억제제 화합물 - Google Patents

금속효소 억제제 화합물 Download PDF

Info

Publication number
KR102061137B1
KR102061137B1 KR1020147023020A KR20147023020A KR102061137B1 KR 102061137 B1 KR102061137 B1 KR 102061137B1 KR 1020147023020 A KR1020147023020 A KR 1020147023020A KR 20147023020 A KR20147023020 A KR 20147023020A KR 102061137 B1 KR102061137 B1 KR 102061137B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
delete delete
disease
candida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147023020A
Other languages
English (en)
Korean (ko)
Other versions
KR20140116939A (ko
Inventor
윌리암 제이. 헉스트라
로버트 제이. 쇼트징거
스티븐 더블유. 래퍼티
Original Assignee
마이코비아 파마슈티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이코비아 파마슈티컬즈, 인코포레이티드 filed Critical 마이코비아 파마슈티컬즈, 인코포레이티드
Publication of KR20140116939A publication Critical patent/KR20140116939A/ko
Application granted granted Critical
Publication of KR102061137B1 publication Critical patent/KR102061137B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147023020A 2012-01-20 2013-01-18 금속효소 억제제 화합물 Active KR102061137B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589076P 2012-01-20 2012-01-20
US61/589,076 2012-01-20
PCT/US2013/022313 WO2013109998A1 (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
KR20140116939A KR20140116939A (ko) 2014-10-06
KR102061137B1 true KR102061137B1 (ko) 2019-12-31

Family

ID=48799718

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147023020A Active KR102061137B1 (ko) 2012-01-20 2013-01-18 금속효소 억제제 화합물

Country Status (14)

Country Link
US (3) US10221160B2 (https=)
EP (1) EP2804858B1 (https=)
JP (1) JP6189865B2 (https=)
KR (1) KR102061137B1 (https=)
CN (1) CN104136427B (https=)
AU (2) AU2013209516A1 (https=)
BR (1) BR112014017751B1 (https=)
CA (1) CA2861339C (https=)
DK (1) DK2804858T3 (https=)
EA (1) EA026209B1 (https=)
ES (1) ES2774267T3 (https=)
IN (1) IN2014DN06792A (https=)
PL (1) PL2804858T3 (https=)
WO (1) WO2013109998A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN00093A (https=) * 2011-06-19 2015-06-19 Viamet Pharmaceuticals Inc
ES2774267T3 (es) * 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
AU2015231226B2 (en) * 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP6572234B2 (ja) * 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
ES2800905T3 (es) * 2014-03-19 2021-01-05 Mycovia Pharmaceuticals Inc Procedimiento para compuesto antifúngico
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
CA2942972A1 (en) * 2014-03-19 2015-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antifungal compound process
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231275B2 (en) * 2014-03-19 2019-03-07 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942936A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP2017512777A (ja) * 2014-03-19 2017-05-25 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
JP6633539B2 (ja) 2014-03-19 2020-01-22 ダウ アグロサイエンシィズ エルエルシー ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換−ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程
RS63566B1 (sr) * 2015-03-19 2022-10-31 Mycovia Pharmaceuticals Inc Antifungalna jedinjenja i procesi izrade
JP6847458B2 (ja) 2015-09-18 2021-03-24 マイコヴィア ファーマシューティカルズ，インコーポレイテッド 抗真菌化合物のプロセス
KR102240920B1 (ko) * 2015-12-30 2021-04-16 브이피에스-3, 엘엘씨 금속 효소 억제 화합물
SMT202100573T1 (it) 2016-12-22 2021-11-12 Calithera Biosciences Inc Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
CN109810049B (zh) * 2018-11-30 2021-01-15 深圳大学 一种含吡啶的化合物及其提取方法
TW202140445A (zh) * 2020-01-17 2021-11-01 大陸商上海森輝醫藥有限公司 四氮唑類化合物的可藥用鹽及其結晶形式、製備方法和用途
CN116528855B (zh) * 2020-10-16 2026-03-13 米拉洛克斯有限责任公司 用于治疗癌症、阿尔茨海默病、血色沉着病和其它病症的金属酶抑制剂
WO2026006142A1 (en) * 2024-06-24 2026-01-02 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Azole compounds useful as inhibitors of voltage-dependent anion channel oligomerization

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007139A1 (en) * 1991-10-10 1993-04-15 Pfizer Limited Triazole antifungal agents
WO1997001552A1 (en) 1995-06-26 1997-01-16 Pfizer Research And Development Company, N.V./S.A. Triazole antifungal agents
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
JP2010007663A (ja) 2008-06-25 2010-01-14 General Electric Co <Ge> ターボ機械においてホイールスペース温度アラームを設定するための方法、システム及び制御装置
JP2010506652A (ja) 2006-10-18 2010-03-04 ビーエヌエル バイオテック シーオー エルティディ 根管充填用根管治療器及びその発熱チップ
JP2010510248A (ja) 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
WO2011133875A2 (en) * 2010-04-24 2011-10-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8304282D0 (en) 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
GB8305377D0 (en) * 1983-02-25 1983-03-30 Pfizer Ltd Antifungal agents
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
GB8415889D0 (en) * 1984-06-21 1984-07-25 Ici Plc Antifungal azole compounds
AU4327585A (en) 1984-06-21 1986-01-02 Imperial Chemical Industries Plc Antifungal azole compounds
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH &amp; CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5358939A (en) 1992-06-25 1994-10-25 Rohm And Haas Company Fungicidal 2-aryl-2,2-disubstituted ethyl-1,2,4-triazoles
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
EP2330905A1 (en) 2008-09-03 2011-06-15 Bayer CropScience AG Use of fungicidal compound compositions for controlling certain rust fungi
US8987315B2 (en) * 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP3483147A1 (en) * 2010-11-13 2019-05-15 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
IN2014MN00093A (https=) * 2011-06-19 2015-06-19 Viamet Pharmaceuticals Inc
WO2012177635A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA025266B1 (ru) * 2011-06-23 2016-12-30 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
JP2014525442A (ja) * 2011-08-30 2014-09-29 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
EP3351541A1 (en) * 2011-12-11 2018-07-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
ES2774267T3 (es) * 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
AU2013209520A1 (en) * 2012-01-20 2014-08-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
EP2948450A4 (en) * 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc METALLOENZYMINHIBITORVERBINDUNGEN
US9688671B2 (en) * 2013-06-12 2017-06-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP6532480B2 (ja) * 2014-04-15 2019-06-19 ダウ アグロサイエンシィズ エルエルシー 殺真菌剤としての金属酵素阻害剤化合物
US9944664B2 (en) * 2014-04-15 2018-04-17 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
FI3562487T3 (fi) * 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007139A1 (en) * 1991-10-10 1993-04-15 Pfizer Limited Triazole antifungal agents
WO1997001552A1 (en) 1995-06-26 1997-01-16 Pfizer Research And Development Company, N.V./S.A. Triazole antifungal agents
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
JP2010506652A (ja) 2006-10-18 2010-03-04 ビーエヌエル バイオテック シーオー エルティディ 根管充填用根管治療器及びその発熱チップ
JP2010510248A (ja) 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
JP2010007663A (ja) 2008-06-25 2010-01-14 General Electric Co <Ge> ターボ機械においてホイールスペース温度アラームを設定するための方法、システム及び制御装置
WO2011133875A2 (en) * 2010-04-24 2011-10-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, vol.6, no.16, pp.2031-2036 (1996.)
Chem Pharm Bull. vol.48, no.7, pp.982-990 (2000.)

Also Published As

Publication number Publication date
DK2804858T3 (da) 2020-03-16
US20150004666A1 (en) 2015-01-01
JP2015504095A (ja) 2015-02-05
AU2013209516A1 (en) 2014-08-28
CA2861339C (en) 2020-08-25
KR20140116939A (ko) 2014-10-06
US20200247779A1 (en) 2020-08-06
US11247981B2 (en) 2022-02-15
US20190169159A1 (en) 2019-06-06
PL2804858T3 (pl) 2020-06-29
EA201491385A1 (ru) 2015-02-27
EP2804858B1 (en) 2019-12-25
EP2804858A1 (en) 2014-11-26
CN104136427B (zh) 2017-03-01
US10526312B2 (en) 2020-01-07
WO2013109998A1 (en) 2013-07-25
BR112014017751A8 (pt) 2021-03-09
EP2804858A4 (en) 2015-07-29
AU2017232080B2 (en) 2019-02-14
AU2017232080A1 (en) 2017-10-12
BR112014017751B1 (pt) 2021-12-07
ES2774267T3 (es) 2020-07-20
IN2014DN06792A (https=) 2015-05-22
US10221160B2 (en) 2019-03-05
JP6189865B2 (ja) 2017-08-30
CA2861339A1 (en) 2013-07-25
CN104136427A (zh) 2014-11-05
EA026209B1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
KR102061137B1 (ko) 금속효소 억제제 화합물
KR101379370B1 (ko) 금속효소 억제제 화합물
AU2014278172B2 (en) Metalloenzyme inhibitor compounds
DK2788343T3 (en) METALLOENZYMIN INHIBITOR COMPOUNDS
KR102240920B1 (ko) 금속 효소 억제 화합물
EA036098B1 (ru) Способ получения противогрибковых соединений
HK1202872B (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140818

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150518

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171219

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190228

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190828

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190828

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190426

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20191024

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190920

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190828

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190426

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191224

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191226

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20221207

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20221207

Start annual number: 4

End annual number: 4